Mycophenolate mofetil hydrochloride

Mycophenolate Mofetil Hydrochloride is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 1998. This drug has a black box warning from the FDA. Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as antirheumatic agents. The directory classifies it as a commercial API with a semi-synthetic source/manufacturing origin. Other names for this substance include Cellcept (TN) and Mycophenolate mofetil (hydrochloride). Its PubChem CID is 6441022.